Latest news
25 items- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- 13D/GSEC Form SC 13G filed by Cellect Biotechnology Ltd.SC 13G - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRCellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin PharmaceuticalsTel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP") (the "Company"), announced today the record date and distribution date for the contingent value rights (the "CVRs") to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the "Merger") and the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd., to EnCellX, Inc., a privately held company based in San Diego, CA (the "Share Transfer"). Upon the closings of the Merger and Share Transfer, the Depositary for the Company's American Depositary Shar
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRCellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin PharmaceuticalsTel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA. Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal. The
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRCellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company's clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company's cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRCellect Biotechnology Reports Second Quarter 2021 Financial and Operating ResultsStrategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news On August 12, the Securities and Exchange Commission (SEC) declared effective the Company's Form F-4 in connection with the proposed strategic merger with Quoin Pharmaceuticals. Quoin is a s
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRThe Securities and Exchange Commission Declared Cellect Biotechnology's Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin PharmaceuticalsSpecial General Meeting of Shareholders Scheduled for September 19, 2021 Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission ("SEC") on August 10, 2021 was declared effective by the SEC on August 12, 2021 (the "Form F-4"). The Form F-4 was filed in connection with the previously announced strategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases. The Company has scheduled a Special General Mee
- SECSEC Form EFFECT filed by Cellect Biotechnology Ltd.EFFECT - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form F-4/A filed by Cellect Biotechnology Ltd. (Amendment)F-4/A - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form F-4/A filed by Cellect Biotechnology Ltd. (Amendment)F-4/A - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form F-4/A filed by Cellect Biotechnology Ltd. (Amendment)F-4/A - Cellect Biotechnology Ltd. (0001671502) (Filer)
- PRCellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin PharmaceuticalsTel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus ("Proxy Statement"), with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmaceuticals. Quoin is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin's leadership team is made up of industry veterans, with extensive relevant executive experience and proven records of recent success in the pharmaceutical i
- SECSEC Form F-4 filed by Cellect Biotechnology Ltd.F-4 - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
- SECSEC Form 6-K filed by Cellect Biotechnology Ltd.6-K - Cellect Biotechnology Ltd. (0001671502) (Filer)
APOP FAQ
6 questionsWhat does Cellect Biotechnology Ltd. do?
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. The company develops ApoTainer, a kit for hematopoietic stem cell transplantation procedures. It has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine...Where does APOP stock trade?
Cellect Biotechnology Ltd. (APOP) is listed on NASDAQ.What sector and industry is APOP in?
Cellect Biotechnology Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did Cellect Biotechnology Ltd. go public?
Cellect Biotechnology Ltd. (APOP) completed its IPO in 2016.What companies are similar to APOP?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare APOP side-by-side with any of them on Quantisnow.How can I track APOP on Quantisnow?
Quantisnow aggregates Cellect Biotechnology Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APOP to receive live email and push alerts on every new disclosure.